Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab
Open Access
- 18 February 2017
- journal article
- case report
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 47 (5), 463-466
- https://doi.org/10.1093/jjco/hyx018
Abstract
Nivolumab, an anti-programmed death-1 antibody, is a breakthrough treatment for several malignancies. Its specific adverse effects caused by autoimmunity are termed immune-related adverse events, which involve several endocrine dysfunctions. Herein, we report two cases of isolated adrenocorticotropic hormone (ACTH) deficiency induced by nivolumab for the treatment of metastatic malignant melanoma. Case 1 was a 39-year-old man and Case 2 was a 50-year-old woman, both of whom presented with progressive melanoma. After 13 courses of nivolumab administration, both cases were diagnosed with adrenal insufficiency. Despite their basal serum ACTH and cortisol levels being low with little response to corticotropin-releasing hormone loading, other anterior pituitary hormone levels were preserved. Based on these endocrinological data, isolated ACTH deficiency was diagnosed. Magnetic resonance imaging showed normal pituitary glands, excluding hypophysitis. Finally, hydrocortisone replacement enabled the patients to continue nivolumab treatment. Therefore, it is important to consider isolated ACTH syndrome as a possible and potentially severe immune-related adverse event of nivolumab, even when head magnetic resonance imaging of affected cases does not show enlargement. We should not misdiagnose hidden immune-related adverse events behind general complaints of malignancies such as general malaise and appetite loss, to allow successful treatment using this beneficial immune checkpoint inhibitor.Keywords
This publication has 20 references indexed in Scilit:
- Medical treatment of renal cancer: new horizonsBritish Journal of Cancer, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Nivolumab: A Review in Advanced MelanomaDrugs, 2015
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institutionEndocrine-Related Cancer, 2014
- ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypothesesActa Endocrinologica, 2013
- Endocrine Side Effects Induced by Immune Checkpoint InhibitorsJournal of Clinical Endocrinology & Metabolism, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Isolated corticotrophin deficiencyPituitary, 2006
- Cytotoxic T-Lymphocyte-Associated Antigen-4 Blockage Can Induce Autoimmune Hypophysitis in Patients With Metastatic Melanoma and Renal CancerJournal of Immunotherapy, 2005
- Failure of the short ACTH test to unequivocally diagnose long‐standing symptomatic secondary hypoadrenalismClinical Endocrinology, 1996